Compare IGR & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | IGR | LXEO |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.2M | 731.3M |
| IPO Year | N/A | 2023 |
| Metric | IGR | LXEO |
|---|---|---|
| Price | $4.72 | $7.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $18.60 |
| AVG Volume (30 Days) | 747.7K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 13.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.88 | $1.45 |
| 52 Week High | $5.70 | $10.99 |
| Indicator | IGR | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 60.12 | 38.80 |
| Support Level | $4.66 | $7.24 |
| Resistance Level | $4.83 | $7.84 |
| Average True Range (ATR) | 0.07 | 0.78 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 53.23 | 16.10 |
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.